Erlotinib Completed Phase 2 Trials for Hepatocellular,Carcinoma Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00287222Bevacizumab and Erlotinib in Inoperable and Metastatic Hepatocellular Carcinoma